Search Results

. 9 Hortobagyi GN Theriault RL Lipton A . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group . J Clin Oncol 1998 ; 16 : 2038 – 2044 . 10 Libshitz

algorithm was used: [early OR adjuvant] AND [breast OR mammary] AND [tumour OR malign * OR carcinom * OR cancer] AND [biphosphonates OR bisphosphonates OR clodronate OR pamidronate OR zoledronic acid OR ibandronate]. The reference lists of all studies

Background Bone-modifying agents (BMAs) are an important component of supportive care for many patients with cancer. These agents include the intravenously administered bisphosphonates pamidronate and zoledronic acid, in addition to denosumab, a

morbidity of bone disease in these patients, guidelines from NCCN, ASCO, International Myeloma Working Group, and European Myeloma Network all recommend use of the bisphosphonates zoledronic acid and pamidronate in patients receiving primary MM therapy. 2

guideline recommended using 1 of 3 treatments: denosumab, zoledronic acid, or pamidronate. The NCCN Guidelines for Breast Cancer 2 also recommend the exact same 3 drugs (to view the most recent version of these guidelines, visit the NCCN Web site at NCCN

Bisphosphonates Bisphosphonates, such as pamidronate and zoledronate, play a fundamental role in minimizing and managing bone-related complications in MM. 14 , 15 Bisphosphonates are drugs that share a phosphorus-carbon-phosphorus backbone and accumulate in the

medications and should be changed. Using Dr. Burstein's example, at Medicare allowable rates, pamidronate costs $29 per month and the physician's office loses $7 on drug costs; zoledronic acid costs $904 per month and the physician's office makes approximately

2002 ; 70 : 11 – 19 . 25. Berenson JR Lichtenstein A Porter L . Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma . Myeloma Aredia Study Group . N Engl J Med 1996 ; 334 : 488 – 493 . 26

2003 ; 169 : 2008 – 2012 . 47 Smith MR McGovern FJ Zeitman AL . Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer . N Engl J Med 2001 ; 345 : 948 – 955 . 48 Tauchmanova L Colao A Lombardi

1982 ; 50 : 893 – 899 . 17 Berenson JR Lichtenstein A Porter L . Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group . N Engl J Med 1996 ; 334 : 488 – 493 . 18